Novartis Acquires Fougera Pharma for $1.5 Billion
05/04/2012
With it's $1.5 billion acquisition of US-based Fougera Pharmaceuticals, Novartis will be the biggest maker of dermatologic generics in the country. The Fougera products will add to those of Novartis's existing generics unit Sandoz.